OrthoPediatrics Corp. (KIDS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 29/100 (MEDIUM), 26.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.08% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course
- OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations
- OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
- OrthoPediatrics (KIDS) Q2 2026 Earnings Call Transcript
- OrthoPediatrics Corp (KIDS) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA ...
- OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
- OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
- OrthoPediatrics (KIDS) Stock Sees Split Analyst Revisions After Mixed Price Target Changes
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for OrthoPediatrics Corp..
Full KIDS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.